GlassScriptPhysician profile
Brett Rossow
NPI 1104239896
$1,903.92
in general payments reported to CMS, 2019-2025
19 companies · $561 in 2025
The $561 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $53.60 · 2023: $289 · 2024: $878 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,728.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $310.60 | 2023-2025 | Gi Genius, Endoflip, Nexpowder |
| Abbvie INC. | $236.88 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $206.04 | 2024-2025 | Voquezna |
| 3-D Matrix, INC. | $159.73 | 2024 | |
| Madrigal Pharmaceuticals | $143.36 | 2025 | Rezdiffra |
| Janssen Scientific Affairs, LLC | $131.81 | 2024 | |
| Boston Scientific Corporation | $121.67 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.41 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Mylan Specialty L.P. | $115.00 | 2023 | Tobi Podhaler |
| Pfizer INC. | $91.75 | 2024-2025 | |
| Ardelyx, INC. | $88.02 | 2024 | Ibsrela |
| Vertex Pharmaceuticals Incorporated | $36.03 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $33.22 | 2025 | Dupixent |
| Merck Sharp & Dohme LLC | $20.84 | 2024 | Dificid |
| Organon LLC | $19.83 | 2025 | Hadlima, Renflexis |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $19.24 | 2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $18.92 | 2024 | |
| Janssen Biotech, INC. | $16.61 | 2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $15.96 | 2024 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Rossow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.